A series of camptothecin prodrugs exhibit HDAC inhibition activity |
| |
| Authors: | Qiwen Zhu Xumeng Yu Qianqian Shen Qiumeng Zhang Mingbo Su Yubo Zhou Jia Li Yi Chen Wei Lu |
| |
| Institution: | 1. Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, PR China;2. Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, PR China;3. National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, PR China |
| |
| Abstract: | Camptothecin plays an important role in clinical cancer treatment, and its derivatives are a favorite of pharmaceutical chemists. Herein, we have designed a series of camptothecin prodrugs that exhibit histone deacetylase (HDAC) inhibition activity based on the synergy effect between HDAC inhibitors and camptothecin derivatives. With the evaluation of stability in buffers or plasma from human or mouse model, an appropriate linker was found, so the active drug can be released efficiently and compound 21a exhibited strong antiproliferative activity in A549 and HCT-116 cell lines. These results indicated that the well-designed prodrug can be promising in cancer treatment. |
| |
| Keywords: | Camptothecin HDAC SAHA Prodrug |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
